MELISSA PERMAN: Open Payments
NPI 1427453406 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$717 in 33 payments from 13 companies in 2025. Trend: 2023 $962 · 2024 $700 · 2025 $717
Food & beverage: $717
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $187 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $84 |
| Novo Nordisk Inc | 4 | $81 |
| Lilly USA, LLC | 3 | $65 |
| PFIZER INC. | 3 | $64 |
| Cleerly, Inc. | 1 | $41 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $29 |
Products named: FARXIGA, Kerendia, AIRSUPRA, Ozempic, Cleerly Ischemia, GARDASIL 9, MOUNJARO, ELIQUIS.
Industry payments across AZ — which companies pay providers there.
